1. Introduction {#sec0005}
===============

*Radix isatidis* is the dry root of *Isatis indigotica* Fort. (Brassicaceae) and is one of the traditional Chinese herbs that is extensively used for the treatment of colds, fever, and influenza. In recent years, granules, eye drops, syrups, and even functional beverages developed from *R. isatidis* have been introduced into the market \[[@bib0005],[@bib0010]\]. Notably, it has also been employed for the treatment of severe acute respiratory syndrome (SARS) and H~1~N~1~-influenza \[[@bib0015],[@bib0020]\].

Relevant studies have shown that progoitrin, epiprogoitrin, and their derivatives (goitrin and epigoitrin) are the main glucosinolates in *R. isatidis*; these chemical constituents reportedly exhibit many biological activities, including antiviral, anti-inflammatory, and anticancer effects \[[@bib0025], [@bib0030], [@bib0035]\]. In addition, progoitrin, epiprogoitrin, goitrin, and epigoitrin account for 34 %, 60 %, 3%, and 1.8 % of total glucosinolates, respectively \[[@bib0040]\]. Epiprogoitrin and progoitrin are converted to corresponding aglycones and other degradation products (epigoitrin/goitrin) by enzymatic hydrolysis through myrosinase in plants or enzymes in the gastrointestinal tract, and this the main biosynthetic pathway of goitrin and epigoitrin \[[@bib0045]\]. Moreover, epiprogoitrin and progoitrin bear a chiral carbon at C-3 as part of their structural skeleton, forming a pair of optical epimers, namely progoitrin (R-progoitrin) and epiprogoitrin (S-progoitrin), respectively ([Fig. 1](#fig0005){ref-type="fig"} A, B). Although the mechanisms underlying these stereoselective functions remain unclear, numerous studies have demonstrated that such epimers \[20(S)-ginsenoside Rg~3~ and 20(R)-ginsenoside Rg~3~ in *Panax notoginseng*\] exhibit various stereoselective activities, such as effects on the cardiovascular \[[@bib0050]\] and immune system \[[@bib0055]\], and antitumor \[[@bib0060],[@bib0065]\] and antidiabetic activities \[[@bib0070]\]. These findings suggest that the stereostructure of the alkane chains is responsible for different pharmacokinetic characteristics and even diverse metabolism patterns after administration.Fig. 1Chemical structures of (A) progoitrin (R-progoitrin), (B) epiprogoitrn (S-progoitrin) and (C) sinigrin (internal standard).Fig. 1

In previous study, a reversed-phase HPLC method was developed that led to the identification of 12 intact glucosinolates, including progoitrin and epiprogoitrin, in traditional Chinese plants \[[@bib0030]\]. In addition, Shi et al. reported an optimized efficient method of HPLC-UV-CD to simultaneously separate and quantify the four main chiral glucosinolates: progoitrin, epiprogoitrin, and R,S-goitrin in crude drugs, decoction pieces, and granules of *R. Isatidis* \[[@bib0075]\]. Recently, a fast, selective, and sensitive LC--MS/MS method coupled with acetonitrile-mediated protein precipitation was recently introduced for detecting (R, S)-goitrin in rat plasma \[[@bib0080]\]. However, to date, no method for the quantification of progoitrin or epiprogoitrin in biological samples has been reported; information on the pharmacokinetics of glucosinolates in *R. isatidis*, particularly progoitrin and epiprogoitrin, is insufficient; consequently, no study has yet performed a systematic comparison of the pharmacokinetics of progoitrin and epiprogoitrin. These obstacles have thus hindered their application.

Accordingly, establishing a simple, reliable method for the pharmacokinetic study of progoitrin and epiprogoitrin is pivotal. This study aimed to develop a method for the pharmacokinetic study of epiprogoitrin and progoitrin both after intravenous (i.v.) and intragastric (i.g.) administrations and to elucidate the influence of 3 (R/S)-configuration on the pharmacokinetics of epiprogoitrin and progoitrin.

2. Material and Methods {#sec0010}
=======================

2.1. Chemical and reagents {#sec0015}
--------------------------

Progoitrin and epiprogoitrin (C~11~H~19~NO~10~S~2~, [Fig. 1](#fig0005){ref-type="fig"}A, B) with purity levels of \>98 % was obtained from Shanghai U-Sea Biotech Co., Ltd. (Shanghai, China), and sinigrin (internal standard, C~10~H~17~NO~9~S~2~, [Fig. 1](#fig0005){ref-type="fig"}C) with purity levels of \>98 % was purchased from Sigma-Aldrich Co., LLC (St. Louis, MO, USA). HPLC-grade acetonitrile and methanol were obtained from Merck (Darmstadt, Germany). Water used in each step was freshly prepared with a Millipore water purification system (MA, USA). All other chemicals and reagents were of analytical grade and commercially available.

2.2. Animals and sampling {#sec0020}
-------------------------

Male Sprague--Dawley rats (7--8 weeks old, 200--250 g) were purchased from the Laboratory Animal Center of Shanghai University of Traditional Chinese Medicine (Shanghai, China) and kept in a light- and temperature-controlled room (room temperature, 21 °C -- 22 °C; relative humidity, 60 %--65 %; 12/12 h light/dark cycle) for 7 days before experiment initiation to adapt them to the laboratory housing conditions. The animals were fed a standard diet and provided ad libitum access to food and tap water. All experimental procedures were approved by the Ethics Committee of Shanghai University of Traditional Chinese Medicine. Animal welfare and experimental procedures were strictly in accordance with the guidelines of the Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine (process number: PZSHUTCM19032501).

A total of 48 male Sprague--Dawley rats were randomly assigned to two groups (namely epiprogoitrin and progoitrin), and the 24 rats in each group were randomised into four groups (n = 6) depending on the i.v. and i.g. administration of epiprogoitrin or progoitrin in different dosages. For i.v. administration, 5 mg of epiprogoitrin (progoitrin) was dissolved in 5 mL water, and each of the six rats received 2 mg/kg through the caudal vein within 1 min. The other three groups of rats were subjected to i.g. administration of 20, 25, or 30 mg/kg epiprogoitrin (progoitrin) dissolved in water. All dosing solutions were prepared immediately before administration. Blood samples (200 μL) were obtained from the periorbital sinus vein before administration (0 h) and 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, and 12 h after administration. The blood samples were then centrifuged at 6000 rpm for 10 min at 4 °C. The reulting plasma thus obtained was transferred into a clean 1.5 mL polypropylene tube and stored at −80 °C until needed.

2.3. LC--MS/MS system and conditions {#sec0025}
------------------------------------

Epiprogoitrin and progoitrin were quantitated using a Shimadzu LCMS-8050 triple quadrupole mass spectrometer coupled with an electrospray ionization (ESI) interface (Shimadzu, Tokyo, Japan). The mass spectrometer was operated in the negative ion mode, and the operating parameters were optimised as follows: nebuliser gas flow, 3 L/min; heating gas flow, 10 L/min; drying gas flow, 10 L/min; interface temperature, 300℃; desolvation line temperature, 250℃; and heat block temperature, 400℃. The ESI--MS/MS parameters are listed in [Table 1](#tbl0005){ref-type="table"} . The descriptions of qualifier transitions for the method including the MS/MS spectra of epiprogoitrin and progoitrin as well as IS are described in [Fig. 2](#fig0010){ref-type="fig"} . Quantitation was achieved according to the multiple reaction monitoring (MRM) mode. Analytical data were processed with LabSolutions v2.0 (Shimadzu).Table 1MRM parameters of epiprogoitrin, progoitrn and IS (negative ion mode).Table 1AnalytesPrecursor ion (m/z)Product ion (m/z)Collision energy (V)Q1 Pre Bias (V)Q3 Pre Bias (V)Epiprogoitrin/progoitrin38897211917Sinigrin(IS)35897211710Fig. 2MS/MS spectrum of epiprogoitrin (A), progoitrin (B) and IS (C).Fig. 2

The processed samples (5 μL) were injected into an ACQUITY UPLC™ HSS T3 column (100 × 2.1 mm i.d., 1.8 μm; Waters Corporation, Milford, MA, USA) maintained at 45 °C. The autosampler tray was maintained at 10 °C, and the sample injection volume was 5 μL. Acetonitrile (A) and 0.1 % aqueous formic acid (B) were used as the gradient mobile phase with a flow rate of 0.3 mL/min. The gradient elution programme was set as follows: 0--2 min, 95 % B; 2--3 min, 5% B; 3--4 min, 95 % B; and finally 95 % B for 0.3 min for reconditioning the column. The total chromatographic time was 4 min, and the retention times of epiprogoitrin, progoitrin, and IS were 1.51, 1.30, and 1.72 min, respectively.

2.4. Stock and working solutions {#sec0030}
--------------------------------

Standard stock solutions of sinigrin (IS), epiprogoitrin, and progoitrin (5 mg/mL) were prepared using pure water. The standard solutions with different concentrations were then serially diluted with pure water and protected from light. All solutions were stored at 4 °C until further analyses.

2.5. Sample pretreatment {#sec0035}
------------------------

An aliquot of 50 μL IS working solution (200 ng/mL) was dried under N~2~ and spiked with 50 μL plasma in a 1.5 mL Eppendorf tube. To this mixture, 250 μL acetonitrile was added. After this solution was vortexed for 30 s, it was centrifuged at 13,500 rpm for 10 min at 4 °C. Subsequently, 150 μL of the clear upper layer was transferred to another 1.5 mL Eppendorf tube for each extract and then dried under N~2~; the dried residues were reconstituted in 200 μL pure water and centrifuged at 13,500 rpm for 10 min at 4 °C. The supernatant was then transferred to vials for LC--MS/MS analyses.

2.6. Method validation {#sec0040}
----------------------

Method validation was conducted on the basis of the currently accepted FDA prescription and per guidelines of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use \[[@bib0085]\].

### 2.6.1. Selectivity {#sec0045}

The selectivity of the method was assessed by comparing MRM chromatograms of six different batches of blank plasma samples from six rats, blank plasma samples from rats spiked with the analytes at LLOQ, and a plasma sample obtained 1 h after oral administration of 25 mg/kg epiprogoitrin/progoitrin. No endogenous substances interfered with the retention times of either analytes or IS.

### 2.6.2. Calibration and lower limit of quantification {#sec0050}

The lower limit of quantification (LLOQ) was defined as the lowest concentration of the calibration curve with acceptable precision (\<15 %) and accuracy (within ±20 %) at which the signal-to-noise ratio was determined to be \>10. The calibration curves were constructed using 12 calibration standards over the range of 2--5000 ng/mL by plotting the peak area ratio of analytes to IS (200 ng/mL) (*y*) versus the nominal concentrations of analytes (*x*) in plasma using a 1/*x* ^2^ weighted linear least-square regression model. The calibration curve was expected to have a correlation coefficient (*r*) of \>0.99.

### 2.6.3. Precision and accuracy {#sec0055}

Accuracy and precision were evaluated using quality control (QC) samples at three concentrations (5, 100, and 4000 ng/mL; n = 6) and LLOQ concentration (2 ng/mL; n = 6) on the same day and over three consecutive days. The calibration curves and samples were prepared and analysed on the same day. The accuracy of the method was calculated as the relative error (RE) and was required to be within ±15 %, whereas the precision of the method was expressed in terms of relative standard deviation (RSD) and was required to be \<15 %.

### 2.6.4. Stability {#sec0060}

The stability of epiprogoitrin and progoitrin in rat plasma was assessed by analysing replicates (n = 6) at three QC concentrations (5, 100, 4000 ng/mL) and LLOQ concentration (2 ng/mL) under various storage conditions and processing procedures. Short-term stability was determined after sample storage at room temperature for 24 h, and long-term stability was assessed by evaluating the QC samples stored at −20 °C for 2 weeks. To assess freeze--thaw stability, the samples were subjected to three freeze -- thaw cycles between −80 °C and room temperature. Autosampler stability was assessed by analysing samples left in the autosampler at 10 °C for 8 h. The calibration curves of freshly prepared standards were used for all stability tests of QC samples.

### 2.6.5. Extraction recovery and matrix effects {#sec0065}

The extraction recovery of the analytes and IS from rat plasma were assessed at three QC concentrations (5, 100, and 4000 ng/mL; n = 6) and LLOQ concentration (2 ng/mL; n = 6), were calculated by comparing the area response in extracted samples with post extraction blanks spiked with equivalent concentration of analyte solution. The matrix effects at three QC concentrations (5, 100, and 4000 ng/mL; n = 6) and LLOQ concentration (2 ng/mL; n = 6) were measured by comparing peak responses of samples spiked after extraction (A) with those of pure water containing equivalent amounts of each analyte and IS (B). The ratio (A/B × 100 %) was used to evaluate the matrix effects. The extraction recoveries and matrix effects of IS were simultaneously evaluated at 200 ng/mL by using the same method.

2.7. Pharmacokinetic analysis {#sec0070}
-----------------------------

The following pharmacokinetic parameters were calculated using a noncompartmental pharmacokinetic model in DAS 3.1 (BioGuider Co., Shanghai, China): the maximum plasma concentrations (C~max~), the time to reach C~max~ (T~max~), total body clearance (CL), volume of distribution (Vd), mean residence time (MRT) were obtained directly from the experimental data. The elimination rate constant (k~e~) was calculated using log-linear regression of the terminal portion of each curve. The elimination half-life (t~1/2~) was calculated as 0.693/k~e~. The area under the curve \[AUC~0-t~, from 0 to the last measurable plasma concentration (C~t~)\] was calculated using the linear trapezoidal method and was extrapolated to infinity \[AUC~(0--∞)~\] using the following formula: AUC~0-∞~=AUC~0-t~＋C~t~/k~e~. Oral bioavailability was defined as the fraction of unchanged drug reaching the systemic circulation following administration through the i.g. route and was measured using the following equation: F (%) = (AUC~i.g.~ × Dose~i.v.~)/(AUC~i.v.~ × Dose~i.g.~) × 100 %.

3. Results and Discussion {#sec0075}
=========================

3.1. Assay development and performance {#sec0080}
--------------------------------------

To develop an accurate, sensitive method for analysing epiprogoitrin/progoitrin, sample preparation is critical for developing a time-saving and effective LC--MS/MS assay. When recovering drugs from matrices, it is vital to use a valid extraction procedure to exclude or minimise matrix interferences. Sample preparation methods, including protein precipitation, solid phase extraction, and liquid--liquid extraction, have been investigated. After evaluating, acetonitrile-mediated precipitation is a better opt, which produced low consumption and achieved good sensitivity in analysis.

Triple quadrupole in MRM mode has become a widely used method. A standard solution was injected into the mass spectrometer to ascertain precursor ions and select product ions using LabSolutions software. A full scan of epiprogoitrin/progoitrin and IS produced molecular ions \[M−H\]^−^ at *m/z* 388 and 358, respectively, and detection in the negative ion mode was more stable than that in the positive ion mode.

In addition, the composition of the mobile phase can influence peak shape and ionization efficiency. Using a gradient mobile phase of acetonitrile and water has been proven to be effective, and the addition of formic acid in water and acetonitrile were used to separate and elute analytes, which combined to produce symmetric chromatographic peaks and provide good separation, when compared with 5 mmol ammonium acetate and other mobile phase. Thus, it is a suitable method for analyses due to the short anlysis time, economic sample pretreatment steps and high sensitivity.

3.2. Method validation {#sec0085}
----------------------

### 3.2.1. Specificity {#sec0090}

Specificity was evaluated by comparing MRM chromatograms of blank plasma samples to corresponding spiked plasma samples. The representative chromatograms of blank plasma, spiked plasma samples (LLOQ), and plasma samples after oral administration of the analytes are shown in [Fig. 3](#fig0015){ref-type="fig"} . It is obvious that no endogenous substances interfered with the ionization of the analytes in any sample. The retention times for epiprogoitrin, progoitrin, and IS were 1.51, 1.40, and 1.72 min, respectively.Fig. 3The typical MRM chromatograms of epiprogoitrin, progoitrin and IS in rat plasma sample: (A) blank plasma sample, (B) blank plasma samples spiked with IS (200 ng/mL), epiprogoitrin and progoitrin respectively (2 ng/mL), (C) plasma samples at 1 h after a single oral administration of analytes (25 mg/kg).Fig. 3

### 3.2.2. Calibration curve and LLOQ {#sec0095}

The calibration curves were established by plotting the ratios of chromatogram peak areas of the analytes to IS. Good linearity was achieved over the concentration range of 2--5000 ng/mL (*r* \> 0.996). The regression equations for epiprogoitrin and progoitrin were *y* = 0.0066*x* + 0.0041 (*r* \> 0.999) and *y* = 0.0061*x* + 0.0010 (*r* \> 0.996), respectively, where *y* represents the peak area ratio of the analytes to IS and *x* denotes the concentration of analytes in the plasma.

The LLOQ for epiprogoitrin/progoitrin was 2 ng/mL based on a signal-to-noise ratio of \>10. The lower limit of detection (LOD) was estimated to be 1 ng/mL (S/N \> 3), and the accuracy (RE) and precision (RSD) at LLOQ were 12.7 % and 10.5 %, respectively.

### 3.2.3. Precision and accuracy {#sec0100}

The intra-day and inter-day accuracy (RE) and precision (RSD) of the analytes in rat plasma at three QC concentrations (5, 100, 4000 ng/mL) and LLOQ concentration (2 ng/mL; n = 6) are shown in Tables S1 and S2 which followed the guidelines of biologic samples set by the FDA, it suggests that accuracy and precision should be within ±15 %.

### 3.2.4. Stability {#sec0105}

The stability of the analytes was assessed under different experimental conditions (Table S3). At each QC concentration, the REs of the short-term, long-term, freeze--thaw, and autosampler stabilities were \< 12.88 %. The obtained results from all stability tests demonstrated that the analytes were stable under diverse conditions; hence, the method was judged to be suitable for routine analysis.

### 3.2.5. Extraction recovery and matrix effects {#sec0110}

The extraction recovery and matrix effects were evaluated to determine the reproducibility of the method. The mean extraction recoveries of epiprogoitrin and progoitrin at the three QC concentrations were \> 91.30 % (Table S4). With respect to the matrix effect, the values ranged from 91.18 % to 107.27 % for all samples.

The validation results indicated that the pretreatment process was efficient and reproducible; in addition, no endogenous substances from plasma significantly affected the analysis.

3.3. Application to pharmacokinetic study {#sec0115}
-----------------------------------------

### 3.3.1. Pharmacokinetics of epiprogoitrin and progoitrin after i.g. administration {#sec0120}

The validated method was successfully applied to pharmacokinetically analyse epiprogoitrin and progoitrin after their oral administration (20, 25, or 30 mg/kg) to rats.

At the same dosage, similar plasma concentration--time curves for both epimers were obtained. The mean plasma concentration--time profiles are depicted in [Fig. 4](#fig0020){ref-type="fig"} , and relevant pharmacokinetic parameters are summarised in [Table 2](#tbl0010){ref-type="table"} .Fig. 4Mean plasma concentration-time curves of epiprogoitrin (A, n = 6) and progoitrin (B, n = 6) after oral administration at the doses of 20, 25, and 30 mg/kg. Vertical bars represent standard deviation.Fig. 4Table 2Pharmacokinetic parameters of epiprogoitrin after oral administration (n = 6) at the doses of 20, 25, and 30 mg/kg. Data were expressed as mean ± S.D.Table 220 mg/kg25 mg/kg30 mg/kgC~max~(μg/L)700.21 ± 177.50745.42 ± 303.171001.95 ± 179.38T~max~(h)1.5 ± 0.551.39 ± 0.561.42 ± 0.65AUC~0-t~(μg/L\*h)2327.36 ± 477.852843.43 ± 448.063299.57 ± 617.90AUC~0-∞~(μg/L\*h)2330.82 ± 478.322840.92 ± 447.863301.09 ± 617.47t~1/2~(h)1.13 ± 0.301.33 ± 0.330.97 ± 0.14MRT~0-t~(h)2.27 ± 0.0702.28 ± 0.252.52 ± 0.07MRT~0-∞~(h)2.28 ± 0.0672.30 ± 0.252.52 ± 0.07Vd(L/kg)15.33 ± 4.6414.57 ± 6.6913.42 ± 4.40CL(L/kg/h)9.55 ± 2.429.23 ± 2.199.41 ± 2.07F(%)9.37.38.7

Observation and comparison of relevant pharmacokinetic parameters at the same dosage yielded interesting results. As shown in [Fig. 4](#fig0020){ref-type="fig"} and [Table 2](#tbl0010){ref-type="table"}, [Table 3](#tbl0015){ref-type="table"} , epiprogoitrin and progoitrin were rapidly absorbed from the gastrointestinal tract after administration and were detectable in plasma from the first blood sampling time point (5 min); subsequently, the plasma concentration sharply increased to reach its peak in approximately 90 min. Epiprogoitrin and progoitrin were rapidly eliminated from the body over a period of approximately 2 h. The AUC and C~max~ values of epiprogoitrin were always higher than those of progoitrin at the same dosage. The peak concentration was higher when a high dose of epiprogoitrin and progoitrin was administered (1001.95 ± 179.38 vs. 740.30 ± 103.27 μg/L) than when a medium (745.42 ± 303.17 vs. 677.98 ± 44.03 μg/L) or low (700.21 ± 177.50 vs. 597.29 ± 161.09 μg/L) dose was administered.Table 3Pharmacokinetic parameters of progoitrin after oral administration (n = 6) at the doses of 20, 25, and 30 mg/kg. Data were expressed as mean ± S.D.Table 320 mg/kg25 mg/kg30 mg/kgC~max~(μg/L)597.29 ± 161.09677.98 ± 44.03740.30 ± 103.27T~max~(h)2.10 ± 0.511.33 ± 0.521.29 ± 0.56AUC~0-t~(μg/L\*h)2190.49 ± 399.702295.82 ± 364.482427.18 ± 331.66AUC~0-∞~(μg/L\*h)2191.51 ± 403.482297.97 ± 364.542430.31 ± 331.97t~1/2~(h)1.17 ± 0.150.99 ± 0.11.12 ± 0.08MRT~0-t~(h)2.59 ± 0.232.61 ± 0.072.63 ± 0.08MRT~0-∞~(h)2.60 ± 0.222.62 ± 0.072.65 ± 0.08Vd(L/kg)12.85 ± 1.7913.89 ± 2.721.06 ± 2.97CL(L/kg/h)7.69 ± 1.218.74 ± 1.358.09 ± 1.86F(%)34.126.920.1

[Table 2](#tbl0010){ref-type="table"}, [Table 3](#tbl0015){ref-type="table"} reveal that a single dose of orally administrated epiprogoitrin or progoitrin exhibited dose-dependent pharmacokinetic profiles in rats ( *r^2^* \> 0.98). None of the other pharmacokinetic parameters, such as t~1/2~, T~max~, MRT, CL, and Vd exhibited significant differences among the three concentrations (p \> 0.05).

### 3.3.2. Pharmacokinetics of epiprogoitrin and progoitrin after i.v. administration {#sec0125}

After rats were given an i.v. injection of epiprogoitrin and progoitrin, both evidently travel in the systemic circulation mainly as themselves; however, this may not be the case upon their i.v. administration. Epiprogoitrin and progoitrin demonstrated significant differences in pharmacokinetic parameters after administration.

[Fig. 5](#fig0025){ref-type="fig"} and [Table 4](#tbl0020){ref-type="table"} indicate that the pharmacokinetic profile of epiprogoitrin was obviously different from that of progoitrin; the C~max~ and AUC values of epiprogoitrin were approximately three-fold higher than those of progoitrin. The half-life of progoitrin was much shorter than that of epiprogoitrin, indicating that progoitrin is more easily eliminated from plasma than epiprogoitrin following a single i.v. administration. Moreover, the CL values of epiprogoitrin were approximately one-third of those of progoitrin. The oral bioavailability of epiprogoitrin and progoitrin also exhibited significant differences. The calculated absolute bioavailability of progoitrin was approximately three-fold higher than that of epiprogoitrin.Fig. 5Mean plasma concentration-time curves of epiprogoitrin and progoitrin after intravenous administration at the dose of 2 mg/kg (n = 6). Vertical bars represent standard deviation.Fig. 5Table 4Pharmacokinetic parameters of epiprogoitrin and progoitrin after intravenous administration (n = 6) at the dose of 2 mg/kg. Data were expressed as mean ± S.D.Table 4ComponentsC~max~(μg/L)t~1/2~(h)AUC~0-t~(μg/L\*h)AUC~0-∞~(μg/L\*h)MRT~0-t~(h)MRT~0-∞~(h)Vd(L/kg)CLz(L/kg /h)progoitrin1197.44 ± 284.761.11 ± 0.154767.903 ± 84.712768.124 ± 84.760.827 ± 0.0360.831 ± 0.0354.185 ± 0.5062.629 ± 0.279epiprogoitrin3276.483 ± 497.3682.89 ± 0.532558.845 ± 311.212563.128 ± 306.9430.851 ± 0.0970.941 ± 0.1977.92 ± 4.560.79 ± 0.092

In terms of epiprogoitrin, the highest dosage was 30 mg/kg in oral administration, which was nearly ten-fold higher than the dosage of i.v. administration, the value of C~max~ after i.v. administration (3276.483 ± 497.368 μg/L) was truly larger than that after oral administration (1001.95 ± 179.38 μg/L) and the value of CL after oral administration (9.41 ± 2.07 L/kg/h) was faster than after i.v. administration (0.79 ± 0.092 L/kg/h). Therefore, after oral administration, epiprogoitrin was cleared faster than after i.v. administration in the body, and the value of t~1/2~ after i.v. administration was higher than that after oral administration.

From the aforementioned results, it is evident that there exist differences between epiprogoitrin and progoitrin not only after oral administration but also after i.v. injection. Progoitrin seemed to undergo relatively extensive metabolism and could be eliminated faster than epiprogoitrin. Additionally, epiprogoitrin is less polar than progoitrin, implying that epiprogoitrin has higher membrane permeability, which may explain why a higher AUC is observed for epiprogoitrin than for progoitrin in vivo \[[@bib0090], [@bib0095], [@bib0100], [@bib0105], [@bib0110]\].

Furthermore, the epimers may undergo directional chiral inversion relative to each other in vivo, which may also be one of the reasons for distinct pharmacokinetic profiles between epiprogoitrin and progoitrin. Oral bioavailability was measured by the following equation: F (%) = (AUC~i.g.~ × Dose~i.v.~)/(AUC~i.v.~ × Dose~i.g.~) × 100 %. The significant difference in bioavailability is mainly due to the difference of AUC after i.v. administration. Because the AUC~i.g.~ values of epiprogoitrin and progoitrin have not significant difference. We have repeated the pharmacokinetic study of epiprogoitrin and progoitrin after i.v. administration, and the results are similar. Therefore, the differences in bioavailability are associated with the AUC~i.v.~ values. And to date, the possible reason of the differences in AUC~i.v.~ values may be the structure of analytes. However, chiral inversion has not yet been reported because these analytes have a similar molecular structure and polarity and the same molecular weight and MS fragments. It is thus challenging to separate them through UHPLC, which is generally used in pharmacokinetic studies with short chromatographic cycles.

4. Conclusions {#sec0130}
==============

To the best of our knowledge, we herein for the first time to describe a novel LC--ESI--MS/MS method with a short running time (4 min), high sensitivity (2 ng/mL), and economical sample pretreatment for studying a pair of epimers (progoitrin and epiprogoitrin) in rat plasma. The results facilitate a comprehensive understanding of the behaviour of these two glucosinolate epimers *in vivo* and highlight pharmacokinetic differences between them that have not yet been reported. After oral administration, progoitrin and epiprogoitrin were rapidly absorbed from the gastrointestinal tract and exhibited dose-independent pharmacokinetic behaviour. The oral bioavailability of epiprogoitrin and progoitrin was 7.7 %--9.3 % and 20.1 %--34.1 %, respectively. Furthermore, after i.v. administration, the pharmacokinetic parameters between epiprogoitrin and progoitrin showed significant differences, which could be attributed to chiral inversion and membrane permeability. Further studies are warranted to validate our findings in the near future.
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